Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diabetic peripheral neuropathy.

D S Younger1

  • 1Division of Clinical Neuromuscular Disease, Department of Neurology, New York University Medical Center, New York 10021, USA.

Drugs of Today (Barcelona, Spain : 1998)
|February 28, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chronic Acquired Demyelinating Polyneuropathy following Renal Transplantation.

Case reports in neurological medicine·2013
Same author

Motor disorders.

Journal of clinical neuromuscular disease·2008
Same author

Lyme neuroborreliosis.

Drugs of today (Barcelona, Spain : 1998)·2004
Same author

Therapy in neuromuscular disease.

Neurologic clinics·2001
Same author

Medical therapies in myasthenia gravis.

Chest surgery clinics of North America·2001
Same author

Motor neuron disease and malignancy.

Muscle & nerve·2000
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Diabetic neuropathy, a complication of diabetes mellitus, involves microangiopathy and immune injury. While glycemic control offers limited benefit, intravenous immune globulin shows promise for specific neuropathic syndromes.

Area of Science:

  • Neurology
  • Endocrinology
  • Immunology

Background:

  • Diabetes mellitus frequently causes clinicopathologic neuropathic syndromes.
  • Microangiopathy, stemming from metabolic, ischemic, and immunologic factors, is the primary driver of diabetic neuropathy.
  • Current treatments like glycemic control offer limited efficacy in preventing disease progression.

Purpose of the Study:

  • To review the diagnosis and evaluation of diabetic neuropathic syndromes.
  • To explore the underlying pathophysiology, including microangiopathy and immune mechanisms.
  • To discuss novel therapeutic approaches for specific diabetic neuropathies.

Main Methods:

  • Comprehensive review of diagnostic methods including history, neurologic examination, electrophysiology, blood tests, cerebrospinal fluid analysis, and nerve/muscle biopsy.

Related Experiment Videos

  • Analysis of pathophysiologic mechanisms, focusing on microangiopathy and immune-mediated injury.
  • Evaluation of therapeutic strategies, including glycemic control and novel treatments like intravenous immune globulin.

    • Main Results:

    • Diabetic neuropathy diagnosis requires a multi-faceted approach.
    • Microangiopathy is central to diabetic neuropathy pathogenesis.
    • Intravenous immune globulin demonstrates potential in treating specific neuropathies like mononeuropathy multiplex and primary demyelinating neuropathy.

    Conclusions:

    • Diabetic neuropathy is a complex condition with significant morbidity.
    • Effective management requires addressing underlying causes and exploring advanced therapies.
    • Intravenous immune globulin represents a promising novel treatment for select immune-mediated diabetic neuropathies.